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Abstract: Selective Androgen Receptor Modulators (SARMs) have anabolic properties but less adverse effects than anabolic androgenic steroids. They are prohibited in both equine and human sports
and there have been several cases of SARMs findings reported over the last few years. The aim of
this study was to investigate the metabolite profile of the SARM ACP-105 (2-chloro-4-[(3-endo)-3hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile) in order to find analytical targets
for doping control. Oral administration of ACP-105 was performed in horses, where blood and
urine samples were collected over a time period of 96 h. The in vivo samples were compared with
five in vitro incubation models encompassing Cunninghamella elegans, microsomes and S9 fractions
of both human and equine origin. The analyses were performed using ultra-high performance
liquid chromatography coupled to high resolution Q ExactiveTM OrbitrapTM mass spectrometry
(UHPLC-HRMS). A total of 21 metabolites were tentatively identified from the in vivo experiments,
of which several novel glucuronides were detected in plasma and urine. In hydrolyzed urine, hydroxylated metabolites dominated. The in vitro models yielded several biotransformation products,
including a number of monohydroxylated metabolites matching the in vivo results. The suggested
analytical target for equine doping control in plasma is a dihydroxylated metabolite with a net
loss of two hydrogens. In urine, the suggested targets are two monohydroxylated metabolites after
hydrolysis with β-glucuronidase, selected both due to prolongation of the detection time and the
availability of reference material from the in vitro models.
Keywords: SARM; Selective Androgen Receptor Modulator; ACP-105; mass spectrometry; doping;
horse; metabolites; microsomes; Cunninghamella elegans

iations.

1. Introduction
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Selective Androgen Receptor Modulators (SARMs) are a novel class of compounds
that are androgen receptor ligands with anabolic properties similar to those of anabolic
steroids in muscle and bone, but with a milder profile of adverse effects, since they are
more tissue selective [1–3]. There have been several clinical trials involving SARMs for
treatment of different diseases such as cachexia and sarcopenia, but so far none of them
have been approved in a pharmaceutical product [3–5]. The pharmacological effects and
limited side effects make them tempting to use as doping agents and they have been on the
World Anti-Doping Agency’s Prohibited List since 2008 [6,7]. SARMs are also included in
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the regulations of the International Federation of Horseracing Authorities (IFHA) and are
prohibited both in and out of equine competition [8]. Many SARMs are readily available to
purchase online and there have been several doping cases involving this substance class in
both humans and horses in the past few years [9–13].
Knowledge of the metabolite profile is important to prolong the detection window
of doping substances, since metabolites may be present in biological samples for a longer
time than the parent compound [14,15]. Besides in vivo administration studies, in vitro
methods, such as microsomal and S9 fraction incubations, are of interest from the perspective of prediction of metabolite patterns. Furthermore, in vitro generated metabolites
from microsome incubations may be used as reference material in both equine and human
doping control in accordance with the International Laboratory Accreditation Cooperation
document ILAC-G7 Accreditation Requirements and Operating Criteria for Horseracing
Laboratories and the World Anti-Doping Agency’s International Standard for Laboratories [16,17]. In addition, the fungus Cunninghamella elegans has been shown to produce
phase I metabolites similar to those of both horses and humans, but the metabolite profile
is often more extensive [18–20]. It has also been possible to scale up the method to purify
metabolites for use as reference substances [21].
The SARM ACP-105 (2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8yl]-3-methylbenzonitrile) was first described in 2008 and structurally characterized with mass
spectrometry in 2013 [22,23]. An in vivo study performed in rats showed that the detected
metabolites in urine consisted of several structural isomers of monohydroxylated and dihydroxylated ACP-105 after β-glucuronidase hydrolysis [14]. A recent equine in vivo study of
metabolites from ACP-105 in urine has also been published, where several phase I metabolites
were presented, such as hydroxylated and dehydrated products, but no phase II metabolites
such as glucuronides were described [24]. However, there is no published information on
neither the phase II metabolism nor the plasma metabolite pattern of this compound in the
horse and suitable analytical targets in these matrices are yet to be determined.
The aim of this study was to investigate the in vivo metabolite profile in equine plasma
and urine after oral administration of ACP-105 and compare with five relevant in vitro
models for possible identification and production of analytical reference material. The
combined information was used to identify suitable analytical targets that can be used in
doping control with ultra-high performance liquid chromatography–high resolution mass
spectrometry (UHPLC-HRMS).
2. Results and Discussion
The identification and time profile analysis of metabolites formed from ACP-105 in
both the in vivo and in vitro experiments were performed by UHPLC-HRMS full scan and
MS/MS product ion scan modes. The reference standard RAD-140 was analyzed in the
beginning and at the end of each batch. The acceptance criteria for batch approval were
<0.02 min drift in retention time and m/z error < 5 ppm. Due to the qualitative properties
of this study, data regarding replicates are not presented, but each biological sample has
been analyzed a minimum of five times with consistent results.
2.1. Detection of Parent ACP-105
Initially, a standard solution of ACP-105 was analyzed and the retention time, ionization
and MS/MS fragmentation were studied. ACP-105 was observed at a retention time of 11.59
min and the main ion in positive mode was C16 H20 ClN2 O+ at m/z 291.1262 corresponding
to [M + H]+ . The structure of ACP-105 is displayed in Figure 1. The aromatic moiety
consists of 2-chloro-3-methylbenzonitrile and the aliphatic moiety consists of 3-methyl-8azabicyclo[3.2.1]octan-3-ol. As seen in Figure 2 and Table A1 in Appendix A, in MS/MS mode,
the main product ions were m/z 273.1149 representing the loss of H2 O, m/z 233.0845 with
the neutral loss of C3 H6 O that occurs due to a cleavage of the aliphatic moiety along with
both the m/z 193.0532 and m/z 179.0373 fragments. The species m/z 167.0373 corresponds
to a fragment with the aromatic moiety intact. The m/z 125.0960 with the neutral loss of
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C8 H7 ClN2 corresponds to a fragment formed by a loss of mainly the aromatic moiety and
m/z 107.0856 represents the same fragment with an additional loss of H2 O. The structural
elucidation of ACP-105 is consistent with studies previously performed by Thevis et al.
where they also made tentative identifications of a variety of in vivo derived hydroxylated
metabolites [14,23].

Figure 1. The structure of ACP-105 (2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct8-yl]-3-methylbenzonitrile).

Figure 2. MS/MS spectrum and suggested cleavage sites for the product ions of ACP-105 with the pre-cursor ion
[C16 H20 ClN2 O]+ with m/z 291.1262. The suggested cleavage sites do not represent the final hydrogen distribution
between the detected fragment and the neutral loss for all fragments, full information available in Table A1 in Appendix A.

ACP-105 was detected in plasma for up to 24 h after administration. The longest
detection time in untreated urine was 24 h, but after hydrolysis with β-glucuronidase the
detection time was increased to 48 h.
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2.2. In Vivo Metabolites
ACP-105 is excreted to a small extent in unchanged form, making the analysis of
metabolites of high interest for doping control. In total, 21 phase I and phase II metabolites
could be tentatively identified in plasma, urine and hydrolyzed urine as demonstrated in
Figure 3. The acceptance criteria for the tentative identification were: mass error < 5 ppm
from the calculated theoretical value, retention time drift < 0.02 min between the different
sample matrices for the same metabolite, chromatographic peaks consisting of a minimum
of five scans and MS/MS spectrum with product ions matching the suggested structure
of the metabolite. There were also signs of several additional structural isomers of some
metabolites but the data did not meet the mentioned criteria and they are thereby not presented. In Figure 3, only the extracted ion chromatograms (isolation width m/z < 2 ppm)
are reported for the metabolites of ACP-105 that have been tentatively identified by the set
criteria described above. Due to this fact, other substances present in the matrices, such as
endogenous compounds, are not displayed.

Figure 3. Combined extracted ion chromatograms of the metabolites of ACP-105 fulfilling the set criteria from the UHPLCHRMS analysis. A full description of the metabolites and their denotations can be found in Table A1 in Appendix A.
(A) metabolites in plasma 12 h after administration; (B) metabolites in urine 24 h after administration and; (C) metabolites
in hydrolyzed urine 24 h after administration. The metabolite labels represent the following metabolic transformations:
monohydroxylation (M1), dihydroxylation (M2), loss of 2H (M3), loss of 2H and monohydroxylation (M4), loss of 2H and
dihydroxylation (M5), loss of 2H and trihydroxylation (M6), glucuronidation (M7), monohydroxylation and glucuronidation
(M8) and dihydroxylation and glucuronidation (M9).

All tentatively identified metabolites and detailed information about their detectability
in plasma, urine and hydrolyzed urine together with information about the fragmentation
can be found in Table A1 in Appendix A. Mass spectra and suggested fragments for all
tentatively identified metabolites can be found in Supplementary Materials Figure S1.
The phase I metabolic transformations resulted in mono-, di- and trihydroxylated
forms also in some cases in combination with a net loss of two hydrogens. The loss of
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two hydrogens could be observed in the aliphatic structure, indicating a double bond
formation. The mechanism could not be elucidated, but possible reactions include loss
of water after hydroxylation, oxidation of an alcohol or dehydrogenation. The net loss of
two hydrogens was also observed in the previous in vivo study and explained as a result
of dehydration [24].
Three monohydroxylated metabolites, M1a-c (C16 H19 ClN2 O2 ) were tentatively identified and detected in hydrolyzed urine where they had the longest detection time. Metabolites M1a and M1c were also detected in plasma, but not in untreated urine, indicating that
glucuronic acid conjugation had taken place.
Two dihydroxylated metabolites, M2a-b (C16 H19 ClN2 O3 ) were detected in hydrolyzed
urine, however, metabolite M2a could also be observed in untreated urine and plasma.
Two metabolites formed by a net loss of two hydrogens, M3a-b (C16 H17 ClN2 O) could be
tentatively identified in hydrolyzed urine. Metabolite M3b could also be seen in untreated
urine, but the detection time was longer in hydrolyzed urine.
Several phase I metabolites formed by a combination of different metabolic transformations were also found, such as two monohydroxylated metabolites with a net loss of
two hydrogens, M4a-b (C16 H17 ClN2 O2 ), that could mainly be found in hydrolyzed urine.
Two dihydroxylated metabolites with a net loss of two hydrogens, M5a-b (C16 H17 ClN2 O3 )
were also tentatively identified. M5a could be found both in untreated as well as in hydrolyzed urine. Metabolite M5b could be found in all analyzed matrices, but with a shorter
detection time in plasma. An additional three trihydroxylated metabolites with a net
loss of two hydrogens, M6a-c (C16 H17 ClN2 O4 ) were also detected in both untreated and
hydrolyzed urine.
Furthermore, seven glucuronides were detected and summarized in Table A1 in Appendix A, out of which, one was the directly glucuronidated parent compound, metabolite
M7 (C22 H27 ClN2 O7 ) that was mainly detected in untreated urine. Four glucuronidated
forms of monohydroxylated metabolites, M8a-M8d (C22 H27 ClN2 O8 ) were also observed.
Metabolites M8a and M8d could be seen in all matrices but had the longest detection time
in untreated urine. Metabolites M8b and M8c could only be detected in untreated urine.
Two glucuronidated forms of dihydroxylated metabolites, M9a-M9b (C22 H27 ClN2 O8 ) were
detected mainly in untreated urine. All these metabolites had a higher intensity and
longer detection time in untreated urine than in hydrolyzed urine, supporting the tentative
identification of these metabolites.
The retention order of the metabolites and the parent compound matched the expected polarity differences based on the tentative identifications (Figure 3 and Table A1 in
Appendix A), e.g., monohydroxylated metabolites (M1a-c) have a longer retention time
than dihydroxylated metabolites (M2a-b).
Structural Elucidation of Major Metabolites
The major metabolites were selected based on their detectability in the different matrices. In plasma, the monohydroxylated metabolite M1c together with the monohydroxylated
glucuronides M8a and M8d had the highest intensities in the investigated time interval, see
Figure 3 and Table A1. In untreated urine, the dihydroxylated metabolite formed by a net
loss of two hydrogens, M5b, together with metabolite M8a and M8d were detected with the
highest intensities over time. The time profiles for the metabolites present in hydrolyzed urine
are shown in Figure 4. The metabolites with the highest intensities and with a detectability of
at least 96 h after administration in hydrolyzed urine were the monohydroxylated metabolites M1a and M1c together with M5b. This combined information was used to select the
five metabolites M1a, M1c, M5b, M8a and M8d for further structural characterization.
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Figure 4. Time profile of the metabolites from ACP-105 present in hydrolyzed urine. The metabolites M1a, M1c and M5b
were detected up to 96 h. The figure shows the time from administration of ACP-105 (x-axis) and the chromatographic peak
area (y-axis).

The diagnostic fragments used for the structural elucidation of the five most abundant
metabolites are shown in Figure 5. For the monohydroxylated metabolite M1a bearing
one additional oxygen in comparison to ACP-105, the fragmentation indicated that the
hydroxylation had taken place on the aliphatic moiety of the structure. The presence of
m/z 142.0527, which represents the aromatic moiety with a loss of Cl• indicates that no
metabolic transformations have occurred on this part of the molecule. The product ions
at m/z 231.0685 and m/z 177.0215 contained two hydrogens less than the corresponding
ACP-105 fragments, suggesting a loss of H2 O somewhere in the ring structure of the
aliphatic moiety. This indicates that the hydroxylation had occurred somewhere on the
aliphatic ring and not on the methyl group.
The monohydroxylated metabolite M1c produced the product ions m/z 233.0842,
m/z 193.0529, m/z 179.0371 and m/z 167.0372 that matched the ACP-105 fragments
and indicated that the aromatic moiety is metabolically unchanged, suggesting that the
hydroxylation had taken place
1 on the aliphatic moiety in this case as well. Furthermore,
the unchanged aliphatic ring fragments m/z 179.0371 and m/z 167.0372 indicated that the
hydroxylation had most likely taken place on the methyl group of the aliphatic moiety as
suggested in previous studies [14].
The dihydroxylated metabolite with a net loss of two hydrogens, M5b also produced
the fragment m/z 167.0372, indicating that the aromatic moiety was metabolically unchanged and that the metabolic transformations had taken place on the aliphatic moiety.
Fragments m/z 177.0215 and m/z 229.0530 were two and four units lower, in comparison
to the corresponding product ions of ACP-105. This suggests that at least two metabolic
transformations had taken place in the ring structure of the aliphatic moiety, probably due
to the loss of H2 O and formation of a double bond.
All diagnostic fragments from the monohydroxylated metabolite M1a matched those
of the monohydroxylated glucuronide M8a. Together with the increased intensity of M1a
and decreased intensity of M8a after hydrolysis, M8a is most likely a phase II metabolite of
M1a. The same relation can be observed for the monohydroxylated metabolite M1c and
the monohydroxylated glucuronide metabolite M8d. This clearly demonstrates the value
of β-glucuronidase hydrolysis in the sample preparation of urine for increased intensity
and extended detection times of illicit use of ACP-105.
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Figure 5. Suggested fragmentation pattern of the major metabolites in comparison with ACP-105. (a) Parent ACP-105—
precursor ion [C16 H20 ClN2 O]+ at m/z 291.1262; (b) monohydroxylated metabolite M1a—precursor ion [C16 H20 ClN2 O2 ]+
at m/z 307.1209; (c) monohydroxylated metabolite M1c—precursor ion [C16 H20 ClN2 O2 ]+ at m/z 307.1209; (d) dihydroxylated metabolite with formed double bond M5b—precursor ion [C16 H18 ClN2 O3 ]+ at m/z 321.1003. The exact position
of the formed double bond within the aliphatic ring structure is not known, but it will change the previous chair formation; (e) monohydroxylated and glucuronidated metabolite M8a—precursor ion [C22 H28 ClN2 O8 ]+ at m/z 483.1532;
(f) monohydroxylated and glucuronidated metabolite M8d—precursor ion [C22 H28 ClN2 O8 ]+ at m/z 483.1530.

2.3. Metabolites From C. elegans Incubations
The metabolite profile of ACP-105 in C. elegans incubates encompasses a range of different phase I and phase II products of interest, such as monohydroxylated, dihydroxylated
and glycosylated forms of ACP-105. The absence of glucuronides was expected, since it
has previously been shown that this fungus produces glycosides instead [21]. The most
relevant findings were that it produced several structural isomers of monohydroxylated
ACP-105 including two with retention time and product ion spectrum matching those of
M1a and M1b from the in vivo study including the set criteria for tentative identification,
see Figure 6. M1a is a major metabolite in equine plasma with a detection time of 24 h.
M1a is also tentatively identified in hydrolyzed urine with a detection time exceeding 96 h
and is an interesting target for doping analysis, making C. elegans incubations a promising
method to produce analytical reference material.
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Figure 6. Extracted ion chromatograms of monohydroxylated ACP-105 [C16 H20 ClN2 O2 ]+ that present the metabolites
detected in hydrolyzed urine, C. elegans incubates and incubates of equine and human microsomes and S9 fractions. In
hydrolyzed urine, the peak at 8.65 min represents metabolite M1a, the peak at 9.01 min represents the metabolite M1b and
the peak at 9.14 min represents the metabolite M1c. The figure shows the retention time in minutes (x-axis) and the relative
mass spectrometric intensity (y-axis).

2.4. Metabolites From Microsome and S9 Fraction Incubations
Both the equine microsomes and the equine S9 fraction produced the monohydroxylated metabolites M1a, M1b and M1c in a similar ratio as in hydrolyzed urine, see Figure 6.
Several additional metabolites were detected, such as the dihydroxylated metabolite with
a net loss of two hydrogens, M5b that could be detected in the equine S9 fraction, but at a
low intensity. Moreover, the glucuronide M7 and the monohydroxylated glucuronide M8d
could be tentatively identified in equine and human microsome and S9 fraction incubates,
but at a low intensity and the data is therefore not presented. The structural elucidation of
the metabolites M1a-M1c was performed by comparing the MS/MS spectra with spectra
from the in vivo analysis along with matching retention times. The results met the set
criteria for tentative identification for the abovementioned metabolites of ACP-105. Thus,
this study has shown the potential to use equine microsome incubates as reference material
for ACP-105 doping analysis.
In addition to the equine microsome and S9 fraction analysis, an inter-species comparison with human microsomes and S9 fractions was performed. This is of interest not
only to compare the metabolite profiles, but also for the future possibility to compare the
results with those of actual human doping control samples. The human microsome and S9
2
fraction incubates both produced
the monohydroxylated M1a. In the S9 fraction incubates
M1c was also tentatively identified, this was done by comparing MS/MS spectra and
retention time with those of the in vivo analysis for both metabolites. The S9 fractions also
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potentially produced metabolite M1b, but it could not be confirmed in this analysis due to
low intensity of the MS signal.
2.5. Suggested Analytical Target for ACP-105 Equine Doping Analysis
The comparison of the plasma, urine and hydrolyzed urine samples with the incubation systems shows the importance of both the in vivo and in vitro models. To confirm the presence of illicit substances in the doping analysis results, reference material is
needed—this is commonly created by organic synthesis, purified and characterized by
NMR. Synthesis methods can be complex and take time to develop. The methods shown in
this paper provide several additional solutions. Samples from microsome incubations with
the substance can be used as reference material in accordance with the current guidelines
for equine and human doping analysis [16,17]. C. elegans incubations can be scaled up and
purified and characterized reference substance can be produced on a larger scale.
In this study, five major metabolites were tentatively identified as observed in
Figure 7. The monohydroxylated metabolites M1a and M1c together with the dihydroxylated metabolite with a loss of two hydrogens, M5b are clearly detectable at 96 h in
hydrolyzed urine, which can be seen in Figure 4, showing that the detection time is even
longer than was tested in this study. The use of the monohydroxylated metabolites M1a
and M1c is recommended as analytical targets in doping analysis after hydrolysis of urine.
This is due to the great increase in detection time after ACP-105 administration in combination with the availability of reference material from several of the in vitro models. In
plasma, metabolite M5b is recommended as an analytical target, but the glucuronidated
monohydroxlated metabolites M8a and M8d could also be used since they have a similar
detection level.

Figure 7. The proposed structures and location of metabolic transformations of the major metabolites from ACP-105. The
information within the brackets indicates if they are present in plasma (P) urine (U), hydrolyzed urine (H.U) and incubates
with C. elegans (C.E), equine microsomes (E.M), equine S9 fractions (E.S), human microsomes (H.M) and human S9 fractions
(H.S). For metabolite M5b, the exact position of the double bond within the aliphatic ring structure is not known.
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3. Materials and Methods
3.1. Chemicals
ACP-105 (2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile) (98.37%) for the administration part of the study was purchased from ChemScene (Monmouth Junction, NJ, USA). RAD-140 (2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile) and ACP-105 for analysis were purchased from
MedChemExpress (Monmouth Junction, NJ, USA) and LGD-4033 (4-[(2R)-2-[(1R)-2,2,2-trifluoro1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)-benzonitrile) was purchased from Toronto
Research Chemicals (North York, ON, Canada). β-nicotinamide adenine dinucleotide phosphate
sodium salt hydrate (β-NADPH), uridine 50-diphosphoglucuronic acid trisodium salt (UDPGA)
and sabouraud dextrose broth were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human pooled liver microsomes, human S9 fractions, individual equine microsomes and equine S9
fractions all at the concentration of 20 mg·ml−1 were purchased from Sekisui Xenotech (Kansas
City, KS, USA). β-glucuronidase from E. coli K12 (80 U·mg−1 at 25 ◦C) was purchased from Roche
(Basel, Switzerland). Formic acid (Optima LC-MS grade) and PierceTM electrospray ionization
(ESI) Positive/Negative Ion Calibration Solution were purchased from Thermo Fisher Scientific
(Waltham, MA, USA). Cunninghamella elegans ATCC 9245 was purchased from LGC Promochem
(Borås, Sweden). Sodium chloride solution (0.86–0.90%) and agar plates (mycological peptone
(10 g·L−1), dextrose (40 g·L−1) and agar (15 g·L−1)) were produced in house at the National Veterinary Institute (SVA, Uppsala, Sweden). Purified water was obtained using Milli-Q® Advantage
A10 with a 0.22-µm filter from Millipore (Burlington, MA, USA). All other chemicals and solvents
were of analytical grade or higher.
3.2. Drug Administration and Sample Collection
Out of six University of California-owned adult Thoroughbred horses (3 mares and
3 geldings; age: 4–8 years; weight: 515.5–569.5 kg), one mare (horse A) and one gelding
(horse B) were randomly selected using a computerized random number generator for drug
administration. Before beginning the study, horses were determined healthy and free of
disease by physical examination, complete blood count and a serum biochemistry panel that
included aspartate aminotransferase, creatinine phosphokinase, alkaline phosphatase, total
bilirubin, sorbitol dehydrogenase, blood urea nitrogen and creatinine. Blood analyses were
performed by the Clinical Diagnostic Laboratories at the William R. Pritchard Veterinary
Medical Teaching Hospital of the University of California, Davis, using their standard
protocols. The horses did not receive any medications for at least two weeks prior to
commencement of this study. Food and water were available ad libitum throughout the
duration of the study. This study was approved by the Institutional Animal Care and
Use Committee of the University of California, Davis (Protocol #20319, date of approval
11 January 2020).
ACP-105 was weighed and suspended in 0.9% NaCl and DMSO (25% of total volume)
and administered orally at a dose of 0.05 mg· kg−1 ACP-105 into the back of the oral cavity
using an oral dosing syringe. A A14-gauge catheter was aseptically placed in one external
jugular vein for sample collection. Blood samples were collected at time 0 (immediately
prior to ACP-105 administration) and at 15, 30, and 45 min, and 1, 1.5, 2, 2.5, 3, 4, 5, 6,
8, 12, 24, 36, 48, 72 and 96 h post ACP-105 administration. Prior to drawing each blood
sample, 10 mL of blood was aspirated and discarded from the catheter and T-Port extension
set (combined internal volume < 2 mL). The catheter was flushed with 10 mL of a dilute
heparinized saline solution (10 IU· mL−1 ) following each sampling time. The jugular vein
catheter, used for sample collection, was removed following the 24-h sample collection and
the blood samples at 36, 48, 72 and 96 h post ACP-105 administration were collected via
direct venipuncture. Blood samples were collected into ethylenediaminetetraacetic acid
(EDTA) containing blood tubes and placed on ice prior to centrifugation at 1620× g for
10 min at 4 ◦ C. Plasma was then immediately transferred into storage cryovials (Phenix
Research Products, Chandler, NC, USA) and stored at −20 ◦ C until analysis. Urine samples
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were collected between 6 and 7, 24, 48, 72 and 96 h post ACP-105 administration. Urine
samples were collected by free catch and were stored at −20 ◦ C until analysis.
3.3. Urine Sample Preparation
3.3.1. Sample Dilution
Urine samples were centrifuged in Eppendorf tubes at 11,500× g for 10 min in a
Sepatech Biofuge 15 (Heraeus, Hanau, Germany) and the supernatant was diluted 1:1 with
aqueous formic acid (0.1%) and transferred to a vial for analysis.
3.3.2. Solid-Phase Extraction with HLB
The urine samples were prepared with a generic method by first diluting 2.0 mL
urine with 2.0 mL aqueous formic acid (0.1%). Oasis HLB 60 mg solid phase extraction
(SPE) cartridges from Waters (Milford, MA, USA) were conditioned with 2.0 mL MeOH
and 2.0 mL aqueous formic acid (0.1%). The samples were loaded on to the cartridge and
washed with 2.0 mL 5% MeOH in water and thereafter eluted using 3.0 mL MeOH. The
solvent was gently evaporated at 50 ◦ C under a stream of nitrogen. The samples were
reconstituted in 600 µL aqueous formic acid (0.1%), centrifuged 11,500× g for 10 min and
transferred to vials for analysis.
3.3.3. Hydrolysis with β-Glucuronidase
Urine samples (2.0 mL) were added to 2.0 mL phosphate buffer (0.1 M, pH 6.10)
and 100 µL β-glucuronidase was added. The samples were placed in a heating bath and
incubated at 50 ◦ C for 2 h. They were cooled to room temperature and thereafter extracted
using the SPE method described in Section 3.3.2. The samples were reconstituted in 700 µL
aqueous formic acid (0.1%) and transferred to vials for analysis.
3.4. Plasma Sample Preparation
Plasma precipitation was performed by transferring 200 µL of plasma samples to an
Eppendorf tube. An amount of 800 µL ice cold acetonitrile was added and the Eppendorf
tubes were mixed using a vortex mixer and stored at 5 ◦ C for 20 min. The samples were
centrifuged at 11,500× g for 10 min and 800 µL of the supernatant was transferred to a
new Eppendorf tube and evaporated to dryness using a vacuum centrifuge Christ RVC 2-8
(Martin Christ, Osterode am Harz, Germany). The samples were thereafter reconstituted in
200 µL aqueous formic acid (0.1%) and transferred to vials for analysis.
3.5. Microsomes and S9 Fraction Incubation
Potassium phosphate buffer (PB) pH 7.4, 50 mM was prepared from 1.0 M KH2 PO4 ,
and 1.0 M K2 HPO4 with the addition of 5 mM MgCl2 . To a 1.5-mL Eppendorf tube, the
following was added; 25 µL PB, 10 µL ACP-105 solution (10 µM, 2.5% MeOH in PB),
10 µL β-NADPH (10 mM in PB), 5 µL of either equine liver microsomes, human liver
microsomes, equine S9 fractions or human S9 fractions. The tubes were incubated in a
Thermomixer Compact from Eppendorf (Hamburg, Germany) at 37 ◦ C and 300 rpm. The
incubation was performed for 90 min, thereafter 10 µL UDPGA (10 mM in PB) was added
and the incubation was continued for an additional 90 min. Several control samples were
used, consisting of UDPGA blank (without addition of UDPGA) substrate blank (without
addition of ACP-105), enzyme blank (without addition of microsomes/S9 fractions) and
a positive control (with LGD-4033 instead of ACP-105). The incubation was terminated
by the addition of 200 µL ice cold acetonitrile, vortexed and centrifuged at 4 ◦ C, 11,500× g
for 10 min in a Micro Star 17R from VWR (Radnor, PA, USA). An amount of 200 µL of
the supernatant was transferred to a new vial and evaporated to dryness in a vacuum
centrifuge. The samples were reconstituted in 100 µL aqueous formic acid (0.1%) and
transferred to vials for analysis.
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3.6. C. elegans Incubation
Fungal suspension (100 µL) was added to agar plates using an inoculating loop. The
agar plates were placed in a Sanyo incubator MIR-253 (Osaka, Japan) together with agar
plates without fungal suspension as control samples. They were incubated at 27 ◦ C and
growth was visible after two days. After five days the fungal mycelium was transferred
to a container with 75.0 mL sodium chloride solution (0.86–0.90%) and stored at 5 ◦ C.
Sabouraud dextrose broth was produced by dissolving 30.0 g in water and autoclaved
at 121 ◦ C for 15 min. An amount of 6.0 mL broth was added to test tubes containing
0.5 mg of ACP-105 and 833 µL of fungal suspension was added. The test tubes were
incubated at 27 ◦ C for five days, control samples without ACP-105 and without fungal
suspension were also incubated. The incubation was terminated by addition of 4.0 mL
ice-cold acetonitrile. From the incubate, 500 µL was transferred to an Eppendorf tube and
centrifuged at 11,500× g for 10 min, the supernatant was transferred to a vial and diluted
1:10 with aqueous formic acid (0.1%) prior to analysis.
3.7. Analysis
The chromatographic separation was performed using a Vanquish UHPLC+ focused
binary pump F and autosampler Vanquish Split Sampler FT from Thermo Fisher Scientific
(Waltham, MA, USA) at 40 ◦ C using an Acquity UPLC® HSS T3 column (2.1 × 100 mm;
particle size 1.8 µm) with an HSS T3 guard column (2.1 × 5 mm; particle size 1.8 µm)
from Waters (Milford, MA, USA). Mobile phase A consisted of 0.1% formic acid in water
and mobile phase B consisted of 0.1% formic acid in acetonitrile. The flow rate was set
to 0.45 mL* min−1 and the initial condition of 3% of mobile phase B was held for 1 min,
before starting a linear gradient from 3–97% of mobile phase B over 16 min and thereafter
isocratically holding at 97% for 4 min. The composition was thereafter changed to 3% of
mobile phase B and held for 3 min for re-equilibration. The injection volume was 5 µL.
The UHPLC system was hyphenated to a Q ExactiveTM OrbitrapTM benchtop mass
spectrometer equipped with a heated electrospray ionization probe (HESI-II), all from
Thermo Fisher Scientific (Waltham, MA, USA) used through the software TraceFinderTM
5.1. The spray voltage vas 3.5 kV in positive ionization, and −3.0 kV in negative ionization.
The capillary temperature was 320 ◦ C and the aux gas heater temperature 400 ◦ C. The
sheath gas was 50, auxiliary gas 10, S-lens RF level 60; all in arbitrary units. Nitrogen was
used as collision gas.
The mass calibration was performed using a calibration solution from the manufacturer containing caffeine, MRFA and Ultramark 1621. Data analysis was performed using
the software FreeStyleTM 1.7 from Thermo Fisher Scientific. The system was operated at a
resolution of 70,000 at m/z 200 at full width at half maximum (FWHM), in full scan mode
(m/z 120-1000). Full scan MS, full scan MS/ddMS2 and data independent MS/MS analysis
were performed. The normalized collision energy for MS/MS analysis varied depending
on the metabolite, but general settings were 10, 35 and 70 %. The isolation window for
MS/MS experiments was ± 0.2 m/z. The metabolite search was performed by utilizing
the theoretical metabolic transformations such as hydroxylations, glucuronidations and
sulfatations and the theoretical chemical compositions. All results were compared with
those of relevant blank reference samples and MS/MS spectra were interpreted and compared with that of the parent compound. The search was performed in both positive and
negative mode. The sensitivity and retention time stability were monitored by injections
of the independent reference compound RAD-140 at the beginning and end of each batch.
Each biological sample was analyzed a minimum of five times.
4. Conclusions
ACP-105 was excreted to a minor extent in unchanged form and is very prone to
metabolic transformations in the horse. A total of 21 metabolites were tentatively identified,
out of which five major metabolites were selected for detailed characterization. These
were the monohydroxylated metabolite M1a and the corresponding monohydroxylated

Metabolites 2021, 11, 85

13 of 17

glucuronide M8a, the monohydroxylated metabolite M1c and the corresponding monohydroxylated glucuronide M8d together with the dihydroxylated metabolite with a net
loss of two hydrogens, M5b. Seven novel phase II metabolites of ACP-105 were tentatively
identified as glucuronides in this study.
This study shows the importance and the usefulness of comparing with relevant
in vitro models. The results showed that with the described method, equine microsomes
can be used as reference material in doping analysis since they produce the major metabolites M1a and M1c. C. elegans also produces the metabolite M1a. The use of the metabolites
M1a and M1c as analytical targets in hydrolyzed urine and metabolite M5b as target in
plasma prolongs the detection time and thereby increases the possibility to detect illicit use
of ACP-105.
Supplementary Materials: The following are available online at https://www.mdpi.com/2218-1
989/11/2/85/s1, Figure S1: Mass spectrum and suggested fragments for all tentatively identified
metabolites (M1a–M9b).
Author Contributions: Conceptualization, M.N.B., H.K., U.B., S.S., M.T. and M.H.; methodology,
M.N.B., H.K., U.B., C.P., S.S., M.T. and M.H.; formal analysis and validation, M.N.B.; investigation,
M.N.B.; resources, H.K. and M.H.; data curation, M.N.B.; writing—original draft preparation, M.N.B.;
writing—review and editing, M.N.B., H.K., U.B., C.P., S.S., M.T. and M.H.; visualization, M.N.B.;
supervision, M.H., U.B., and C.P.; funding acquisition, H.K. and M.H. All authors have read and
agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: This study was approved by the Institutional Animal
Care and Use Committee of the University of California, Davis (Protocol #20319, date of approval
11 January 2020).
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available within the article and
supplementary material.
Acknowledgments: The authors would like to thank Börje Tidstedt and the members of the Department of Chemistry, Environment and Feed Hygiene at the National Veterinary Institute (SVA)
Uppsala Sweden, for instrumental resources and Arminas Pakulnis for the assistance with the
C. elegans experiments.
Conflicts of Interest: The authors declare no conflict of interest.

Appendix A
Table A1. The metabolites from ACP-105 tentatively identified in plasma, urine and hydrolyzed urine (H. urine) which
represents urine treated with β-glucuronidase. The theoretical m/z (Th. m/z) is based on the elemental composition and
the experimental m/z (Ex. m/z) is from analysis with positive electrospray ionization (ESI). The column Detectability
after administration indicates for how long the analyte was detectable in the different matrices after administration and
represents horse A and B in the format of A/B h. The samples were taken 0–96 h from the time of administration. A
total of 21 metabolites from ACP-105 were tentatively identified, labeled M1a–M9b consisting of hydroxylations, loss of
two hydrogens, glucuronidations and combinations of these metabolic transformations.
Metabolite

Elemental
Composition
[M+H]+

rt
(min)

ACP-105
C16 H20 ClN2 O+

11.59

Th. m/z (T)
Ex. m/z (E)
ppm

Fragment
m/z (ppm)

Neutral Loss

Detectability
after
Administration

T: 291.1259
E: 291.1262
−1.2 ppm

273.1149 (1.4)
233.0845 (−2.2)
193.0532 (−2.6)
179.0373 (−1.4)
167.0373 (−1.5)
125.0960 (0.7)
107.0856 (−0.7)

H2 O
C3 H6 O
C6 H10 O
C7 H12 O
C8 H12 O
C8 H7 ClN2
C8 H7 ClN2 , H2 O

Plasma:
Urine:
H. urine:

24/12 h
24/24 h
48/48 h
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Table A1. Cont.
Metabolite

Elemental
Composition
[M+H]+

Th. m/z (T)
Ex. m/z (E)
ppm

Fragment
m/z (ppm)

Neutral Loss

Detectability
after
Administration

T: 307.1208
E: 307.1209
−0.5 ppm

289.1105 (−1.0)
231.0685 (−0.7)
195.0918 (−0.7)
189.0215 (−0.6)
177.0215 (−0.6)
142.0527 (−1.4)
107.0856 (−0.7)

H2 O
C3 H8 O2
C3 H8 O2 , HCl
C6 H14 O2
C7 H14 O2
C7 H14 O2 , Cl•
C8 H5 ClN2 , 2xH2 O

Plasma:
Urine:
H. urine:

36/24h
96/96 h

T: 307.1208
E: 307.1210
−0.8 ppm

289.1104 (−0.7)
271.0999 (−1.0)
233.0477 (−0.4)
193.0529 (−1.1)
179.0371 (−0.3)
142.0527 (−1.4)
105.0696 (2.6)

H2 O
2xH2 O
C4 H10 O
C6 H10 O2
C7 H12 O2
C7 H14 O2 , Cl•
C8 H7 ClN2 , 2xH2 O

Plasma:
Urine:
H. urine:

48/72 h

9.14

T: 307.1208
E: 307.1209
−0.5 ppm

289.1104 (−0.7)
271.0999 (−1.0)
233.0842 (−0.9)
193.0529 (−1.1)
179.0371 (−0.3)
167.0372 (−0.9)
123.0805 (−0.5)
105.0700 (−1.2)

H2 O
2xH2 O
C3 H6 O2
C6 H10 O2
C7 H12 O2
C8 H12 O2
C8 H7 ClN2 , H2 O
C8 H7 ClN2 , 2xH2 O

Plasma:
Urine:
H. urine:

36/24 h
96/96 h

7.03

T: 323.1157
E: 323.1159
−0.7 ppm

305.1053 (−0.6)
231.0685 (−0.7)
195.0918 (−0.7)
189.0215 (−0.6)
177.0215 (−0.6)
142.0527 (−1.4)

H2 O
C3 H8 O3
C3 H8 O3 , HCl
C6 H14 O3
C7 H14 O3
C7 H14 O3 , Cl•

Plasma:
Urine:
H. urine:

36/48 h
-/7 h
48/24 h

T: 323.1157
E: 323.1161
−1.3 ppm

305.1053 (−0.6)
287.0948 (−0.9)
247.0635 (−1.0)
229.0529 (−0.9)
194.0840 (−1.0)
179.0604 (0.0)
142.0527 (−1.4)

H2 O
2xH2 O
C3 H8 O2
C3 H10 O3
C3 H10 O3 , Cl•
C4 H12 O3 , HCl
C7 H14 O3 , Cl•

Plasma:
Urine:
H. urine:

72/48 h

10.11

T: 289.1102
E: 289.1106
−1.4 ppm

271.1000 (−1.3)
243.0685 (−0.7)
233.0477 (−0.4)
179.0371 (−0.3)
177.0214 (0.0)
142.0526 (−0.7)
111.0805 (−0.6)

H2 O
C2 H6 O
C4 H8
C7 H10 O
C7 H12 O
C7 H12 O, Cl•
C9 H7 ClN2

Plasma:
Urine:
H. urine:

24/24 h

11.56

T: 289.1102
E: 289.1108
−2.1 ppm

271.1000 (−1.3)
229.0523 (1.7)
203.0370 (0.2)
183.0321 (−0.8)
165.0215 (−0.7)

H2 O
C3 H8 O
C5 H10 O
C8 H10
C8 H12 O

Plasma:
Urine:
H. urine:

24/7 h
48/48 h

8.88

T: 305.1051
E: 305.1054
−0.9 ppm

287.0949 (−1.2)
245.0842 (−0.9)
229.0529 (−0.9)
194.0840 (−1.0)
179.0605 (−0.7)
142.0527 (−1.4)
123.0805 (−0.5)

H2 O
C2 H4 O2
C3 H8 O2
C3 H8 O2 , Cl•
C4 H10 O2 , HCl
C7 H12 O2 , Cl•
C8 H5 ClN2, H2 O

Plasma:
Urine:
H. urine:

-/7 h
48/48 h

9.83

T: 305.1051
E: 305.1053
−0.6 ppm

223.0270 (−0.6)
177.0215 (−0.6)
142.0527 (−1.4)
111.0441 (−0.5)

C6 H10
C7 H12 O2
C7 H12 O2 , Cl•
C10 H11 ClN2

Plasma:
Urine:
H. urine:

72/48 h

rt
(min)

M1a
Monohydroxylation
C16 H20 ClN2 O2 +

8.65

M1b
Monohydroxylation
C16 H20 ClN2 O2 +

9.00

M1c
Monohydroxylation
C16 H20 ClN2 O2 +

M2a
Dihydroxylation
C16 H20 ClN2 O3 +

M2b
Dihydroxylation
C16 H20 ClN2 O3 +

7.63

M3a 1
Loss of 2H
C16 H18 ClN2 O+

M3b 1,2
Loss of 2H
C16 H18 ClN2 O+

M4a 1
Monohydroxylation
+ loss of 2H
C16 H18 ClN2 O2 +

M4b 1
Monohydroxylation
+ loss of 2H
C16 H18 ClN2 O2 +
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Table A1. Cont.
Metabolite

Elemental
Composition
[M+H]+

rt
(min)

Th. m/z (T)
Ex. m/z (E)
ppm

Fragment
m/z (ppm)

Neutral Loss

Detectability
after
Administration

9.17

T: 321.1000
E: 321.1005
−1.6 ppm

303.0897 (−0.8)
285.0793 (−1.4)
229.0530 (−1.3)
179.0375 (−2.6)

H2 O
2xH2 O
C3 H8 O3
C7 H10 O3

Plasma:
Urine:
H. urine:

24/7 h
24/24 h

9.57

T: 321.1000
E: 321.1003
−0.9 ppm

303.0896 (−0.5)
285.0792 (−1.0)
275.0949 (−1.3)
229.0530 (−1.3)
217.0529 (−1.0)
193.0528 (−0.6)
177.0215 (−0.6)
167.0372 (−0.9)
142.0527 (−1.4)

H2 O
2xH2 O
C1 H2 O2
C3 H8 O3
C4 H8 O3
C6 H8 O3
C7 H12 O3
C8 H10 O3
C7 H12 O3 , Cl•

Plasma:
Urine:
H. urine:

36/36 h
96/96 h
96/96 h

7.21

T: 337.0950
E: 337.0953
−1.1 ppm

319.0847 (−1.0)
179.0372 (−0.9)
142.0527 (−1.4)
105.0336 (−1.1)

H2 O
C7 H10 O4
C7 H12 O4 , Cl•
C9 H7 ClN2, 3xH2 O

Plasma:
Urine:
H. urine:

72/24 h
72/48 h

H2 O
C3 H6 O4
C3 H6 O4 , HCl
C6 H12 O4
C7 H12 O4
C7 H12 O4 , Cl•

Plasma:
Urine:
H. urine:

-/6 h
72/24 h
72/72 h

Plasma:
Urine:
H. urine:

24/24 h
6/24 h

M5a 1,2
Dihydroxylation
+ loss of 2H
C16 H18 ClN2 O3 +

M5b 1
Dihydroxylation
+ loss of 2H
C16 H18 ClN2 O3 +

M6a 1
Trihydroxylation
+ loss of 2H
C16 H18 ClN2 O4 +

Trihydroxylation
+ loss of 2H
C16 H18 ClN2 O4 +

7.47

T: 337.0950
E: 337.0951
−0.5 ppm

319.0845 (−0.4)
231.0686 (−1.1)
195.0918 (−0.7)
189.0215 (−0.6)
177.0215 (−0.6)
142.0527 (−1.4)

Trihydroxylation
+ loss of 2H
C16 H18 ClN2 O4 +

9.04

T: 337.0950
E: 337.0955
−1.7 ppm

319.0847 (−1.0)
301.0742 (−1.3)

H2 O
2xH2 O

8.95

T: 467.1580
E: 467.1580
0.0 ppm

291.1259 (0.0)
273.1155 (−0.8)
233.0841 (−0.5)
193.0529 (−1.1)
179.0371 (−0.3)
167.0372 (−0.9)
142.0527 (−1.4)
107.0856 (−0.7)

C6 H8 O6
H2 O, C6 H8 O6
C3 H6 O, C6 H8 O6
C6 H10 O, C6 H8 O6
C7 H12 O, C6 H8 O6
C8 H12 O, C6 H8 O6
C7 H14 O, Cl• ,
C6 H8 O6
C8 H5 ClN2 , 2xH2 O,
C6 H8 O6

Plasma:
Urine:
H. urine:

-/6 h
24/24 h
-

7.13

T: 483.1529
E: 483.1531
−0.4 ppm

307.1210 (−0.8)
289.1104 (−0.7)
231.0685 (−0.7)
195.0919 (−1.2)
189.0216 (−1.1)
177.0215 (−0.6)
142.0527 (−1.4)

C6 H8 O6
H2 O, C6 H8 O6
C3 H8 O2 , C6 H8 O6
C3 H8 O2 , HCl,
C6 H8 O6
C6 H14 O2 , C6 H8 O6
C7 H14 O2 , C6 H8 O6
C7 H14 O2 , Cl• ,
C6 H8 O6

Plasma:
Urine:
H. urine:

36/36 h
48/48 h
6/7 h

7.61

T: 483.1529
E: 483.1527
0.4 ppm

465.1428 (−1.2)
289.1105 (−1.0)
271.0999 (−1.0)
217.0529 (−1.0)
179.0372 (−0.9)
123.0805 (−0.5)

H2 O
H2 O, C6 H8 O6
2xH2 O, C6 H8 O6
C4 H10 O2 , C6 H8 O6
C7 H12 O2 , C6 H8 O6
C8 H7 ClN2 , H2 O,
C6 H8 O6

Plasma:
Urine:
H. urine:

6/7 h
-

M6b 1

M6c 1,2

M7

Glucuronidation
C22 H28 ClN2 O7 +

M8a

Monohydroxylation
+ glucuronidation
C22 H28 ClN2 O8 +

M8b

Monohydroxylation
+ glucuronidation
C22 H28 ClN2 O8 +
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Table A1. Cont.
Metabolite

Elemental
Composition
[M+H]+

M8c

Monohydroxylation
+ glucuronidation
C22 H28 ClN2 O8 +

M8d

Monohydroxylation
+ glucuronidation
C22 H28 ClN2 O8 +

M9a

Dihydroxylation
+ glucuronidation
C22 H28 ClN2 O9 +

M9b

Dihydroxylation
+ glucuronidation
C22 H28 ClN2 O9 +

rt
(min)

Th. m/z (T)
Ex. m/z (E)
ppm

7.85

T: 483.1529
E: 483.1524
1.0 ppm

307.1210 (−0.8)
289.1105 (−1.0)
271.1001 (−1.7)
233.0481 (−2.1)
193.0530 (−1.6)
179.0372 (−0.9)
142.0528 (−2.1)

C6 H8 O6
H2 O, C6 H8 O6
2xH2 O, C6 H8 O6
C4 H10 O, C6 H8 O6
C6 H10 O2 , C6 H8 O6
C7 H12 O2 , C6 H8 O6
C7 H14 O2 , Cl• ,
C6 H8 O6

Plasma:
Urine:
H. urine:

24/24 h
-

8.00

T: 483.1529
E: 483.1530
−0.2 ppm

465.1425 (−0.5)
307.1209 (−0.5)
289.1104 (−0.7)
271.0999 (−1.0)
233.0841 (−0.5)
193.0528 (−0.6)
179.0371 (−0.3)
167.0372 (−0.9)
123.0805 (−0.5)

H2 O
C6 H8 O6
H2 O, C6 H8 O6
2xH2 O, C6 H8 O6
C3 H6 O2 , C6 H8 O6
C6 H10 O2 , C6 H8 O6
C7 H12 O2 , C6 H8 O6
C8 H12 O2 , C6 H8 O6
C8 H7 ClN2 , H2 O,
C6 H8 O6

Plasma:
Urine:
H. urine:

36/36 h
96/48 h
-/7 h

6.21

T: 499.1478
E: 499.1470
1.6 ppm

323.1155 (0.5)
305.1053 (−0.6)
287.0947 (−0.5)
231.0685 (−0.7)
195.0919 (−1.2)
142.0527 (−1.4)

C6 H8 O6
H2 O, C6 H8 O6
2xH2 O, C6 H8 O6
C3 H8 O3 , C6 H8 O6
C3 H8 O3 , HCl,
C6 H8 O6
C7 H14 O3 , Cl• ,
C6 H8 O6

Plasma:
Urine:
H. urine:

48/24 h
6/7 h

6.52

T: 499.1478
E: 499.1478
0.0 ppm

481.1376 (−0.9)
323.1160 (−1.0)
305.1053 (−0.6)
287.0948 (−0.9)
247.0635 (−1.0)
231.0685 (−0.7)
195.0918 (−0.7)
142.0527 (−1.4)

H2 O
C6 H8 O6
H2 O, C6 H8 O6
2xH2 O, C6 H8 O6
C3 H8 O2 , C6 H8 O6
C3 H8 O3 , C6 H8 O6
C3 H8 O3 , HCl,
C6 H8 O6
C7 H14 O3 , Cl• ,
C6 H8 O6

Plasma:
Urine:
H. urine:

48/24 h
-

Fragment
m/z (ppm)

Neutral Loss

Detectability
after
Administration

1

The position of the double bond within the aliphatic ring structure is not known. 2 Marked metabolites were tentatively identified at a
low intensity and/or co-eluting with background analytes with an m/z ± 0.2 from the analyte of interest, causing the MS/MS spectrum to
contain a combination of fragments from analytes giving a lower level of identification.
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